Valproic acid (as semisodium valproate)
Indication
Manic episodes associated with bipolar disorder.
MHRA Drug Safety Update - Medicines related to valproate: risk of abnormal pregnancy outcomes
Amber level 0
Brand:
Depakote
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
LSCMMG is adopting the local decision made prior to April 2013
Update March 2016 — there is a risk of abnormal pregnancy outcomes following maternal use. See DoH Drug Safety Alert for more information.
The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: